Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (521-530 of 754) with videos related to

Pageof 76
Sort By:
The New England Journal of Medicine|October 3, 1996
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsF M Sacks, M A Pfeffer, L A Moye, et al.
International Journal of Cardiology|February 2, 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCATJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
Circulation. Heart Failure|May 24, 2011
Dyssynchrony, contractile function, and response to cardiac resynchronization therapyDorit Knappe, Anne-Catherine Pouleur, Amil M Shah, et al.
JACC. Heart Failure|April 12, 2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, et al.
American Heart Journal|February 23, 2020
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapibJean-Claude Tardif, Marie-Pierre Dubé, Marc A Pfeffer, et al.
European Heart Journal|June 7, 2006
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeJohn J V McMurray, Fredrik L Andersson, Simon Stewart, et al.
Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.
Circulation|November 21, 2007
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery diseaseScott D Solomon, Julie Lin, Caren G Solomon, et al.
Circulation. Heart Failure|January 26, 2018
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic AssociationsPeter van der Meer, Niels Grote Beverborg, Marc A Pfeffer, et al.
European Heart Journal. Acute Cardiovascular Care|August 1, 2025
Long-term outcomes of recurrent myocardial infarction: a nationwide Danish studyDaniel Mølager Christensen, Deewa Zahir, Caroline Hartwell Garred, et al.
Pageof 76

Showing results (521-530 of 754) with videos related to

Sort By:
Pageof 76
The New England Journal of Medicine|October 3, 1996
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsF M Sacks, M A Pfeffer, L A Moye, et al.
International Journal of Cardiology|February 2, 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCATJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
Circulation. Heart Failure|May 24, 2011
Dyssynchrony, contractile function, and response to cardiac resynchronization therapyDorit Knappe, Anne-Catherine Pouleur, Amil M Shah, et al.
JACC. Heart Failure|April 12, 2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, et al.
American Heart Journal|February 23, 2020
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapibJean-Claude Tardif, Marie-Pierre Dubé, Marc A Pfeffer, et al.
European Heart Journal|June 7, 2006
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeJohn J V McMurray, Fredrik L Andersson, Simon Stewart, et al.
Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.
Circulation|November 21, 2007
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery diseaseScott D Solomon, Julie Lin, Caren G Solomon, et al.
Circulation. Heart Failure|January 26, 2018
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic AssociationsPeter van der Meer, Niels Grote Beverborg, Marc A Pfeffer, et al.
European Heart Journal. Acute Cardiovascular Care|August 1, 2025
Long-term outcomes of recurrent myocardial infarction: a nationwide Danish studyDaniel Mølager Christensen, Deewa Zahir, Caroline Hartwell Garred, et al.
Pageof 76